SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a sharp intraday reversal, prompting discussions about potential market manipulation and the strength of the AI sector following Nvidia's earnings; traders are actively debating whether this pullback represents a buying opportunity or the start of a deeper correction, with some pointing to possible Yen carry trade issues.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia's stock is trending amid upgrades from analysts, though some community members express concern over valuation relative to competitors and potential interconnect hurdles in the AI sector. Despite strong earnings, the stock experienced a selloff, leading to discussions about a possible short squeeze and whether AI constitutes a bubble.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing heavy volatility, sparking discussions about a potential market correction and whether dip-buying strategies will continue to pay off. Some community members are pointing to broader macroeconomic concerns and the influence of crypto markets, while others are eyeing key support levels for potential reversals. The conversation highlights uncertainty around near-term market direction.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing volatility, sparking debates about a potential market bottom and the influence of large institutional players. Community discussions revolve around whether this dip presents a buying opportunity or signals a deeper correction, with some pointing to macro factors and potential liquidations as drivers. Sentiment is mixed, with bullish and bearish arguments clashing amidst the price swings.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending due to strong Q3 earnings and raised FY26 guidance, sparking bullish sentiment among investors; discussions include the impact of e-commerce growth and a planned move to the Nasdaq. Community members are debating whether Walmart's performance signals broader economic strength or if it's a safe haven during market uncertainty, while also pondering its valuation relative to tech companies.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the price of Bitcoin fluctuates, impacting MicroStrategy's value as a major BTC holder; the community is closely watching key support levels. Discussions revolve around analyst Tom Lee's commentary and potential short squeezes, with some expressing concerns about solvency and potential liquidation. Recent whale activity and overall market sentiment add to the volatility.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending following a target price increase from UBS and rising memory prices linked to AI data-center demand, fueling discussions about its growth potential. Community members are weighing the bullish outlook against concerns of an overbought condition after the stock's significant year-to-date gains. Discussions also focus on potential short-term pullbacks versus long-term opportunities in the semiconductor space.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is trending as traders assess its volatile movements amidst optimism in the AI sector. Community discussions revolve around dip-buying strategies and potential profit-taking points, especially with upcoming earnings from key semiconductor players like NVDA. The ongoing government shutdown and concerns about AI valuations add to the uncertainty surrounding this leveraged ETF.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending downwards, frustrating investors who cite strong deliveries and question the stock's valuation relative to peers. Community members speculate about market manipulation and potential short squeezes while bracing for upcoming earnings. Despite the negative price action, some investors remain optimistic, viewing the current dip as a buying opportunity based on the company's long-term potential.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending due to Bitcoin's price volatility, sparking debates on whether to buy the dip or brace for further declines; some community members point to potential manipulation and significant ETF outflows as bearish signals, while others highlight oversold conditions and historical patterns as reasons for optimism, with key options levels around \$50 also in focus.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AstraZeneca (AZN) on Wednesday announced the unveiling of its expanded manufacturing facility in Texas aimed at doubling the production of its drug Lokelma.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251014866366/en/AstraZeneca-unveils-expanded-manufacturing-facility-in-Texas">invested</a> $445 million to expand the facility, it said. The unveiling <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-announces-4.5-billion-dollar-investment-in-virginia/ch67yQKR31I">follows</a> the groundbreaking last week at the drugmaker’s $4.5 billion manufacturing facility in Albemarle County, Virginia. &nbsp;The investments are part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then.The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for AstraZeneca’s Lokelma, a prescription medicine for the treatment of high levels of potassium in the blood in adults, a condition known as hyperkalemia.The facility supplies the drug to more than 50 countries worldwide. <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a> said that through the expansion and development of a new 9,000 square foot building, two novel manufacturing lines will be added, along with enhancements to support drug substance and drug product laboratory testing, warehousing, additional manufacturing utilities, and administrative space.The increased investment in the U.S. by drugmakers follows President Donald Trump’s push to move pharmaceutical manufacturing to American soil. Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products effective October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.On Stocktwits, retail sentiment around AZN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.AZN stock is up by 29% this year and by about 8% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-says-oral-glp-1-drug-reduced-blood-sugar-levels-in-two-late-stage-trials/ch6nxr4R3Nm">Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The international biopharmaceutical company AstraZeneca office building in Shanghai, China on June 27, 2025. 

AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 

Equity

The facility in Coppell, which employs more than 250 people, is the sole global manufacturing facility for the company’s Lokelma. 


Drugmaker AstraZeneca (AZN) on Thursday said that it will invest $4.5 billion in a new manufacturing facility in Virginia amid President Donald Trump’s push to move pharmaceutical manufacturing to American soil.The investment is $500 million more than initially planned and is intended to support the enhanced manufacturing capability of a broader range of medicines, including weight management, metabolic, and cancer technologies, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251009456597/en/AstraZeneca-plans-to-increase-investment-and-scope-of-its-Virginia-manufacturing-facility-to-%244.5-billion-creating-3600-new-jobs">said.</a>The new facility will be located at Rivanna Futures in Albemarle County, and the company expects the facility to create 600 skilled jobs and an additional 3000 jobs to support the facility’s construction. The construction will start immediately, and the facility is expected to be operational in the next four to five years, the company added.The new announcement is part of the company’s commitment to invest $50 billion in the U.S. by 2030, with the goal of reaching $80 billion in total revenue by then. AstraZeneca CEO Pascal Soriot on Thursday noted that the investment in Virginia is the largest in the company’s history.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume dropped from ‘normal’ to ‘low’ levels.<figure class="image"><img style="aspect-ratio:996/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_1_46_59_PM_png_5e85c683cb.webp" alt="AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="996" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 1:47 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>Last month, President Trump announced on Truth Social that the United States will impose a 100% tariff on branded and patented pharmaceutical products starting October 1, unless manufacturers actively build plants in the country. Trump is also pressuring drugmakers to lower drug prices in the U.S. to levels comparable to those paid by other wealthy nations.Last month, AstraZeneca <a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-plans-ordinary-share-listing-in-us/chDub9CR376">announced</a> that it plans to list its ordinary shares on the New York Stock Exchange, replacing its existing U.S. listing of American Depositary Receipts (ADRs) on Nasdaq. The move is part of the company’s efforts to expand its access to capital, it had said, while noting that the U.S. has the world’s largest and most liquid public markets by capitalization.AZN stock is up by 31% this year and by 10% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reportedly-intends-to-launch-longer-range-model-y-variant-in-china/ch67xJOR315">Tesla Reportedly Intends To Launch A Longer Range Model Y Variant In China</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Announces $4.5B Investment In Virginia 

The investment is $500 million more than initially planned, intended to support the enhanced manufacturing capability of a broader range of medicines, according to the company. 

AstraZeneca (AZN) on Friday launched an at-home delivery service for its Flumist influenza vaccine ahead of the upcoming flu season.Flumist is a vaccine that is sprayed into the nose to help protect against influenza in people aged two through 49 years. However, it may not prevent influenza in everyone who gets vaccinated, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250815310613/en/FLUMIST-Influenza-Vaccine-Live-Intranasal-the-nations-only-nasal-spray-flu-vaccine-now-available-for-home-delivery">stated</a>.The vaccine was initially approved by the U.S. Food and Drug Administration in 2003. It can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals aged 2-17 years.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AZN">AZN</a> rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Adults aged 18 and older can visit the Flumist website and click to order, following which they will be directed to complete a medical screening questionnaire. These submissions will then be reviewed by a licensed healthcare provider with ASPN Pharmacies, an independent online specialty pharmacy, to determine eligibility.Once eligibility is confirmed and insurance verified, the vaccine will be prescribed and shipped to the consumer’s home by Polaris Pharmacy Services, a specialty pharmacy, in temperature-controlled packages.The vaccine will be delivered with clear administration instructions, storage guidance, and disposal instructions, AstraZeneca said. Once received, the vaccine should be stored in the refrigerator until use. The home delivery service will be available only in 34 states for the upcoming flu season due to local pharmacy laws, the company said. However, AstraZeneca is eyeing making the service available across all 48 contiguous states in future seasons.Flumist, meanwhile, will continue to be available in doctors’ offices and pharmacies for administration by healthcare professionals across the nation, the company added.AZN stock is up by 20% this year but down by about 8% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/big-short-investor-michael-burry-cuts-stake-in-estee-lauder/chsPoDFRdfW">‘Big Short’ Investor Michael Burry Cuts Stake In Estee Lauder By A Whopping 25% – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine

Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.

AstraZeneca (AZN) on Monday said that its investigational drug Baxdrostat reduced systolic blood pressure (SBP) compared with placebo at 12 weeks in a late-stage study evaluating the drug in uncontrolled or treatment-resistant hypertension.Nasdaq-listed shares of the company traded 0.3% higher at the time of writing.The reduction in systolic blood pressure was both statistically significant and clinically meaningful, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-met-primary-and-all-secondary-endpts-in-baxhtn-phiii-trial.html">said</a> in a statement. Baxdrostat was generally well tolerated with a favourable safety profile in the trial, where patients with uncontrolled or treatment-resistant hypertension received the investigational drug or placebo on top of standard of care.According to <a href="https://stocktwits.com/symbol/AZN">AstraZeneca</a>, there are 1.3 billion people worldwide living with hypertension, a medical condition characterised by consistently high blood pressure levels, which can, over time, damage blood vessels and vital organs. While uncontrolled hypertension persists despite treatment with two or more medications, resistant hypertension, a more severe form, remains elevated despite treatment with three or more medications.A key contributor to hypertension is aldosterone, a hormone that increases blood pressure by promoting sodium and water retention. Baxdrostat is an oral, small-molecule investigational drug that inhibits an enzyme responsible for the synthesis of aldosterone in the adrenal gland.AstraZeneca acquired Baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023. A contingent value right of $10 per share in cash is payable to former CinCor shareholders upon the submission of a new drug application either in the U.S. or Europe.AstraZeneca said on Monday that the data from the late-stage trial will be shared with regulatory authorities around the world, but did not detail when it will seek approval for the drug from the U.S. Food and Drug Administration.Baxdrostat is currently being investigated in clinical trials for hypertension, primary aldosteronism, chronic kidney disease, and the prevention of heart failure in high-risk hypertensive patients.On Stocktwits, retail sentiment around AstraZeneca is unchanged within the ‘neutral’ territory over the past 24 hours, accompanied by ‘low’ message volume.<figure class="image"><img style="aspect-ratio:1366/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_9_51_14_AM_png_716900ba11.webp" alt="AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits" width="1366" height="126"><figcaption>AZN's Sentiment Meter and Message Volume as of 9:50 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>AZN stock was up by 9% this year but down by about 9% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gsk-seeks-fda-approval-for-rsv-vaccine-in-more-adults/ch8ByXHR5Vp">GSK Seeks FDA Approval For RSV Vaccine In More Adults: Retail Sees No Reason To Shift Their Bullish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the AstraZeneca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AstraZeneca Stock Rises As Experimental Drug Lowers Blood Pressure In Late-Stage Study, Retail’s Yet To React

The reduction in systolic blood pressure in the trial was both statistically significant and clinically meaningful, the company said in a statement.

Current Price	$40.74
Prev Close	$41.50
Open	$42.32
Dividend Yield	N/A
50-Day Moving Average	$41.82
Beta	N/A
Avg. Volume	16,557.26
PE Ratio	N/A

52-Week High	$44.04
52-Week Low	$27.34
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

QQMG
Invesco ESG NASDAQ 100 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest QQMG News

QQMGInvesco ESG NASDAQ 100 ETF